A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2018
At a glance
- Drugs AG 10 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; First in man
- Sponsors Eidos Therapeutics
- 07 Aug 2018 According to an Eidos Therapeutics media release, complete data will be presented at poster presentation at Heart Failure Society of America 22nd Annual Scientific Meeting in September 2018.
- 03 May 2018 According to an Eidos Therapeutics media release, results from this trial were presented at the 16thInternational Symposium on Amyloidosis 2018.
- 03 May 2018 According to an Eidos Therapeutics media release, status changed from recruiting to completed.